课题基金 / 基金详情

Phage-based assay to measure daptomycin concentration in biological fluids

Phage-based assay to measure daptomycin concentration in biological fluids
基于噬菌体的测定生物体液中达托霉素浓度
批准号:
8832109
负责人:
Martyn Darby
金额:
$25.7万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2015
资助国家:
美国
项目状态:
已结题
起止时间:
2015-02-01 至 2016-08-31

项目摘要

项目成果

Martyn Darby的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
 DESCRIPTION (provided by applicant): Severe Gram positive infections are difficult to treat and associated with high mortality in hospital settings. Daptomycin is a broad spectrum antibiotic that has been successfully used to treat persisting Gram positive infections, including skin and soft tissue infections, right-sided endocarditis, and bacteremia. Daptomycin is also highly effective against drug-resistant strains such as methicillin-resistant S. aureus (MRSA) and vancomycin-resistant enterococci (VRE). Current daptomycin dosing guidelines are derived from limited studies in healthy individuals, where pharmacokinetics is highly predictable. Unfortunately, daptomycin pharmacokinetics are highly variable in the critically ill patients that typically receive the drug. This leads to sub-therapeutic dosing, increased rates of treatment failure, and recently, the emergence of daptomycin- resistant strains. Therapeutic monitoring of daptomycin concentrations would thus enable clinicians to adjust doses in order to maintain an effective circulating concentration, ultimately improving outcomes and preventing adverse effects. Unfortunately, there is no FDA-approved test to measure daptomycin concentrations in a clinical setting. Multiple clinical studies have concluded that current daptomycin dosing guidelines for critically ill and septic patients need to be reevaluated and adjusted, and regular measurement of daptomycin levels in these patients are needed to ensure effective treatment. To address this critical need, Affinergy has begun development of an assay to measure circulating daptomycin concentrations. We have identified a series of phage that bind with high affinity and specificity to daptomycin, and we are developing an ELISA-type assay using phage as a highly sensitive detection reagent. At the conclusion of Phase 1, we expect to have a technology that can be scaled up in Phase 2 for use by clinicians and researchers to measure daptomycin concentrations in biological fluids.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
A novel peptide assay for hepcidin clinical monitoring
  • 批准号:
    10698746
  • 项目类别:
  • 资助金额:
    $61.38万
  • 财政年份:
    2023
  • 负责人:
    Martyn Darby
  • 依托单位:
A Rapid Point of Care Test for APOL1 Renal Risk Alleles
  • 批准号:
    10257344
  • 项目类别:
  • 资助金额:
    $68.5万
  • 财政年份:
    2021
  • 负责人:
    Martyn Darby
  • 依托单位:
A Rapid Point of Care Test for APOL1 Renal Risk Alleles
  • 批准号:
    10441565
  • 项目类别:
  • 资助金额:
    $74.14万
  • 财政年份:
    2021
  • 负责人:
    Martyn Darby
  • 依托单位:
Rapid assay to monitor vancomycin levels at the point of care in hemodialysis patients
  • 批准号:
    10398206
  • 项目类别:
  • 资助金额:
    $68.28万
  • 财政年份:
    2020
  • 负责人:
    Martyn Darby
  • 依托单位:
海外基金